2024-03-28T17:20:54Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_387B5794018D
2024-03-23T02:12:34Z
openaire
documents
urnserval
serval:BIB_387B5794018D
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
16779715
000238642700003
Palmer
A.J.
author
Roze
S.
author
Valentine
W.J.
author
Ray
J.A.
author
Frei
A.
author
Burnier
M.
author
Hess
B.
author
Spinas
G.A.
author
Brändle
M.
author
article
2006-05-27
2006-05-27
Swiss medical weekly
1424-7860
0036-7672
journal
136
21-22
346-352
Albuminuria/drug therapy
Albuminuria/economics
Angiotensin II Type 1 Receptor Blockers/administration & dosage
Angiotensin II Type 1 Receptor Blockers/economics
Angiotensin II Type 1 Receptor Blockers/therapeutic use
Antihypertensive Agents/administration & dosage
Antihypertensive Agents/economics
Antihypertensive Agents/therapeutic use
Biphenyl Compounds/administration & dosage
Biphenyl Compounds/economics
Biphenyl Compounds/therapeutic use
Cohort Studies
Cost Savings
Creatinine/blood
Diabetes Mellitus, Type 2/drug therapy
Diabetes Mellitus, Type 2/economics
Diabetic Nephropathies/drug therapy
Diabetic Nephropathies/economics
Follow-Up Studies
Humans
Hypertension/complications
Hypertension/drug therapy
Hypertension/economics
Life Expectancy
Markov Chains
Practice Guidelines as Topic
Switzerland
Tetrazoles/administration & dosage
Tetrazoles/economics
Tetrazoles/therapeutic use
Time Factors
Treatment Outcome
eng
60_published
peer-reviewed
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
https://serval.unil.ch/notice/serval:BIB_387B5794018D
https://serval.unil.ch/resource/serval:BIB_387B5794018D.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_387B5794018D6
Copying allowed only for non-profit organizations